208 related articles for article (PubMed ID: 22162056)
1. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
Bozic C; Richman S; Plavina T; Natarajan A; Scanlon JV; Subramanyam M; Sandrock A; Bloomgren G
Ann Neurol; 2011 Nov; 70(5):742-50. PubMed ID: 22162056
[TBL] [Abstract][Full Text] [Related]
2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
3. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
4. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
5. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Olsson T; Achiron A; Alfredsson L; Berger T; Brassat D; Chan A; Comi G; Eraksoy M; Hegen H; Hillert J; Jensen PE; Moiola L; Myhr KM; Oturai A; Schippling S; Siva A; Sorensen PS; Trampe AK; Weber T; Potts J; Plavina T; Paes D; Subramanyam M; Wiendl H; Dib H; Uren D; Hemmer B; Buck D
Mult Scler; 2013 Oct; 19(11):1533-8. PubMed ID: 23459571
[TBL] [Abstract][Full Text] [Related]
6. Anti-JC virus antibodies: implications for PML risk stratification.
Gorelik L; Lerner M; Bixler S; Crossman M; Schlain B; Simon K; Pace A; Cheung A; Chen LL; Berman M; Zein F; Wilson E; Yednock T; Sandrock A; Goelz SE; Subramanyam M
Ann Neurol; 2010 Sep; 68(3):295-303. PubMed ID: 20737510
[TBL] [Abstract][Full Text] [Related]
7. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
Bozic C; Subramanyam M; Richman S; Plavina T; Zhang A; Ticho B
Eur J Neurol; 2014 Feb; 21(2):299-304. PubMed ID: 24894998
[TBL] [Abstract][Full Text] [Related]
8. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of JC virus serostatus stability among multiple sclerosis patients.
Alroughani R; Akhtar S; Ahmed S; Al-Hashel J
Mult Scler Relat Disord; 2018 Feb; 20():132-135. PubMed ID: 29414286
[TBL] [Abstract][Full Text] [Related]
10. Anti-JC virus antibody titres increase over time with natalizumab treatment.
Raffel J; Gafson AR; Malik O; Nicholas R
Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
12. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
[TBL] [Abstract][Full Text] [Related]
13. Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
Aladro Y; Terrero R; Cerezo M; Ginestal R; Ayuso L; Meca-Lallana V; Millán J; Borrego L; Martinez-Ginés M; Rubio L; de Andrés C; Miralles A; Guijarro C; Rodríguez-García E; García-Dominguez JM; Muñoz-Fernández C; López de Silanes C; Gómez M; Thuissard I; Cerdán M; Palmí I; Díaz-Garzón LF; Meca-Lallana J
J Neurol Sci; 2016 Jun; 365():16-21. PubMed ID: 27206867
[TBL] [Abstract][Full Text] [Related]
14. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
15. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
[TBL] [Abstract][Full Text] [Related]
16. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
Hegen H; Auer M; Bsteh G; Di Pauli F; Plavina T; Walde J; Deisenhammer F; Berger T
PLoS One; 2017; 12(3):e0174005. PubMed ID: 28319193
[TBL] [Abstract][Full Text] [Related]
17. Anti-JC virus seroprevalence in a Finnish MS cohort.
Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
[TBL] [Abstract][Full Text] [Related]
18. JCV epidemiology in MS (JEMS)--epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients--Portuguese data.
da Silva AM; Santos ME;
J Neurol Sci; 2014 Feb; 337(1-2):119-22. PubMed ID: 24369270
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.
Lin J; Bettin P; Lee JK; Ho JK; Sadiq SA
J Neuroimmunol; 2013 Aug; 261(1-2):123-8. PubMed ID: 23800458
[TBL] [Abstract][Full Text] [Related]
20. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]